PhaseBio to Present at Cowen and Company 40th Annual Health Care Conference

Loading...
Loading...

MALVERN, Pa. and SAN DIEGO, Feb. 26, 2020 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. PHAS, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will present a company overview at the Cowen and Company 40th Annual Health Care Conference on Wednesday, March 4, at 10:40 a.m. EST in Boston.

A live and archived version of the presentation will be available on the company's website at https://investors.phasebio.com.

About PhaseBio
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases. The company's pipeline includes: PB2452, a novel reversal agent for the antiplatelet therapy ticagrelor; PB1046, a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio's proprietary elastin-like polypeptide (ELP) technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including PB1046, and drives both internal and partnership drug-development opportunities.

PhaseBio is located in Malvern, PA and San Diego, CA. For more information, please visit www.phasebio.com.

Investor Contact:
John Sharp
PhaseBio Pharmaceuticals, Inc.
Chief Financial Officer
(610) 981-6506
john.sharp@phasebio.com

Media Contact:
Jason Spark
Canale Communications
(619) 849-6005
jason@canalecomm.com

Loading...
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...